Centric Wealth Management Grows Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Centric Wealth Management lifted its stake in Eli Lilly and Company (NYSE:LLY) by 1.2% in the 4th quarter, HoldingsChannel reports. The firm owned 13,537 shares of the company’s stock after acquiring an additional 156 shares during the period. Eli Lilly and Company makes up 2.5% of Centric Wealth Management’s portfolio, making the stock its 7th largest holding. Centric Wealth Management’s holdings in Eli Lilly and Company were worth $7,891,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its holdings in Eli Lilly and Company by 2.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,560,553 shares of the company’s stock worth $2,658,438,000 after buying an additional 125,242 shares during the period. Northern Financial Advisors Inc boosted its stake in shares of Eli Lilly and Company by 66.1% in the fourth quarter. Northern Financial Advisors Inc now owns 2,483 shares of the company’s stock worth $1,447,000 after acquiring an additional 988 shares during the period. Welch & Forbes LLC raised its stake in Eli Lilly and Company by 2.6% during the 4th quarter. Welch & Forbes LLC now owns 133,093 shares of the company’s stock valued at $77,583,000 after purchasing an additional 3,340 shares during the period. Capital Performance Advisors LLP purchased a new position in Eli Lilly and Company in the 4th quarter worth approximately $217,000. Finally, Apollon Wealth Management LLC boosted its stake in Eli Lilly and Company by 50.8% in the 4th quarter. Apollon Wealth Management LLC now owns 13,679 shares of the company’s stock worth $7,974,000 after purchasing an additional 4,609 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Down 0.2 %

Shares of NYSE:LLY traded down $1.54 during trading on Wednesday, reaching $776.23. 1,252,671 shares of the company were exchanged, compared to its average volume of 3,067,264. The business’s fifty day simple moving average is $761.22 and its 200-day simple moving average is $674.88. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. Eli Lilly and Company has a 12-month low of $419.80 and a 12-month high of $800.78. The firm has a market capitalization of $737.73 billion, a PE ratio of 114.24, a P/E/G ratio of 1.45 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the prior year, the business earned $1.62 EPS. The business’s revenue for the quarter was up 26.0% compared to the same quarter last year. On average, research analysts anticipate that Eli Lilly and Company will post 13.82 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be issued a $1.30 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.67%. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Analysts Set New Price Targets

LLY has been the subject of several research analyst reports. Barclays raised their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. The Goldman Sachs Group lifted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Finally, DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research report on Wednesday, February 21st. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.